Allogeneic graft-versus-hepatoblastoma effect

Pediatric Blood and Cancer

Volumn 46, Issue 4, 2006, Pages 501-505

  Inaba, Hiroto ^a   Handgretinger, Rupert ^a   Furman, Wayne ^a   Hale, Gregory ^a   Leung, Wing ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Graft versus tumor effect; Hematopoietic stem cell transplantation; Hepatoblastoma

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TSUKUBAENOLIDE;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CASE REPORT; CHILD; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEPATOBLASTOMA; HLA MATCHING; HUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOBLASTOMA; HISTOCOMPATIBILITY TESTING; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 33644670040     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20404     Document Type: Article

References (23)

1. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: Hepatoblastoma. Oncologist 2000;5:445-453.
2. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy. A report from the Childrens Cancer Study Group. J Clin Oncol 1991;9:2167-2176.
3. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fiuorouracil therapy for hepatoblastoma: A Pediatric Oncology Group study. J Clin Oncol 1993;11:96-99.
4. Van Turnout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: A report from the Children's Cancer Group. J Clin Oncol 1997;15:1190-1197.
5. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000;18:2665-2675.
6. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: A pediatric oncology group phase II study. J Clin Oncol 2002;20:3438-3444.
7. Kasow KA, Handgretinger R, Krasin MJ, et al. Possible allogeneic graft-versus-tumor effect in childhood melanoma. J Pediatr Hematol Oncol 2003;25:982-986.
8. Katzenstein HM, Rigsby C, Shaw PH, et al. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 2002;24:751-755.
9. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-389.
10. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994;120:646-652.
11. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
12. Feinstein L, Sandmaier B, Maloney D, et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann NY Acad Sci 2001;938:328-337.
13. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021-2030.
14. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004;22:3886-3892.
15. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
16. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762.
17. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
18. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996;17:1061-1067.
19. McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: A randomized, controlled trial. Gastroenterology 1998;115:28-35.
20. Bertz H, Afting M, Kreisel W, et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999;24:1185-1189.
21. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004;172:644-650.
22. Iyengar R, Handgretinger R, Babarin-Dorner A, et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003;5:479-484.
23. Leung W, Iyengar R, Leimig T, et al. Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 2005;54:389-394.